With The positive result of the first phase III study, coupled with the positive responses of nurses and patients, AcelRx Pharmaceuticals (ACRX) saw a substantial increase in its share price, reaching a high of $5.19 in late November. As is often…
Tag: Adam Feuerstein
BioTech wrap up for December 21st $ALXA $FOLD
$ALXA and $FOLD Commentary, Merry Christmas and a happy new year to everyone!
My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano
My video commentary on The Negative Article about Alexza 12/5/12, written by Jason Napodano, CFA which can be found at http://propthink.com/alexza-meaningfully-overvalued-following-its-latest-rally/4120